Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Type 2 Diabetes: full-pipeline trial registry
120 of 328 indexed Type 2 Diabetes trials are currently recruiting.
Corpus placement: #22 of 28,707 conditions by registered trial count.
328 US clinical trials · 120 currently recruiting · #22 of 28,707 conditions by registered trial count
Type 2 Diabetes: 328 US clinical trials tracked, 120 recruiting.
Type 2 Diabetes is the subject of 328 registered US clinical trials on ClinicalTrials.gov, 120 of them currently open to new participants. 60 are in Phase 3-4 (later-stage) and 50 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 20 of these trials.
Enrollment posture brief
Registry condition type-2-diabetes
OPEN 120 | RECR 37% | LATE 60 | EARLY 50 | RANK #22 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Advanced Cancer (37% recruiting · 123 trials)
Type 2 Diabetes lists 120 open slots (37% of 328 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Type 2 Diabetes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Type 2 Diabetes recruits in line with its size-band peers.
120 of 328 indexed trials (36.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Type 2 Diabetes trials is spread across many organizations.
Eli Lilly and Company accounts for 20 of 328 trials (6.1%). 153 distinct sponsors appear on at least one study for this condition label.
-
Typical Type 2 Diabetes enrolment sits around 96 participants.
Median target enrolment is 96 among the 328 trials that report a genuine target (sentinel values excluded). 166 of those (50.6%) plan for fewer than 100 participants.
-
Type 2 Diabetes research is mostly interventional.
290 interventional and 38 observational studies make up this index (88.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
328 total, page 4 of 7
Preventing Diabetes in Latino Families
Arizona State University
NCT05228522
Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)
Foundation for Atlanta Veterans Education and Research
NCT05040087
Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes
Charles Drew University of Medicine and Science
NCT05765214
Group Versus Traditional Prenatal Care for Diabetes
Washington University School of Medicine
NCT03301792
TRE in Type 2 Diabetes (See Food Study 3)
University of Minnesota
NCT05290246
Continuous Glucose Monitoring Following Hospital Discharge
Kathleen Dungan
NCT05360056
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
University of Alabama at Birmingham
NCT05098470
Conditional Cash Transfer Intervention to Improve T2DM
State University of New York at Buffalo
NCT05559892
Effect of a Pharmacist-led, Collaborative Practice on Clinical Outcomes in Persons with Diabetes
Methodist Health System
NCT05995262
Exercise Resistance in Type 2 Diabetes
AdventHealth Translational Research Institute
NCT01911104
Glycemic Control, Type II Diabetes, Parathyroidectomy
The Cleveland Clinic
NCT05761743
Diabetes Nutrition Education and Healthy Food Resource for AIANs With T2D
Colorado State University
NCT06077162
Recreational Basketball to Increase Participation in Diabetes Prevention
Kaiser Permanente
NCT05066542
The Bennett Kids PowerUP Project
Wake Forest University Health Sciences
NCT05858580
The Medically Reproducing Bariatric Surgery (MRB) II Study
Durham VA Medical Center
NCT06363747
Understanding and Optimizing Care for Young Adults With Type 1 and Type 2 Diabetes Mellitus Transitioning to Adult Care
Massachusetts General Hospital
NCT05229718
DIALYSIS-TIR Study
University of Texas Southwestern Medical Center
NCT06042153
Application of Time Restriction Feeding in Patients With Type 2 Diabetes Mellitus
OhioHealth
NCT05015504
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
Mayo Clinic
NCT05264727
The Effects of Glucagon on Hepatic Metabolism
Adrian Vella
NCT05500586
Continuous Glucose Monitoring System Feasibility in Youth With T2D
University of California, San Francisco
NCT06089070
Multilevel Lifestyle Intervention to Improve Physical Function in Older Adults With Type 2 Diabetes
The University of Texas Health Science Center at San Antonio
NCT06173804
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4
University of Pennsylvania
NCT04323189
Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring With Mobile Health: Improving Outcomes for Older Adults With Mild Cognitive Impairment
NYU Langone Health
NCT05601583
Daily Protein Pacing Effects on HbA1c in Type 2 Diabetics
Skidmore College
NCT05355090
Personalized Nutrition Therapy Using Continuous Glucose Monitoring to Improve Outcomes in Type 2 Diabetes Mellitus
University of Minnesota
NCT06465693
Type 2 Diabetes With Antiplatelet Drugs
Tabula Rasa HealthCare
NCT05053828
Extension for Community Health Outcomes (ECHO) Diabetes Program
University of Florida
NCT06552923
Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment
AstraZeneca
NCT02917057
Gene x Behavior Interaction in the Look AHEAD Study
The Miriam Hospital
NCT01270763
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
VIVUS
NCT00553787
Vitamin D and Type 2 Diabetes Study
Tufts Medical Center
NCT01942694
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
Eli Lilly and Company
NCT03987919
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company
NCT05872620
Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin
AstraZeneca
NCT00673231
Improving Self Management Skills of Older Adults With Diabetes
Stanford University
NCT01943357
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
AstraZeneca
NCT00643851
Bronx A1c: Bring it Down for Health
Albert Einstein College of Medicine
NCT00797888
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
Eli Lilly and Company
NCT05362058
Dapagliflozin DPPIV Inhibitor add-on Study
AstraZeneca
NCT00984867
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
Eli Lilly and Company
NCT05662332
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
Sanofi
NCT02058160
A 2-Month Safety Follow-Up Trial
Mannkind Corporation
NCT00741429
A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
Eli Lilly and Company
NCT01624259
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
Sanofi
NCT00299871
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
Intarcia Therapeutics
NCT01455870
Fresh Food Farmacy: A Randomized Controlled Trial
John B Bulger, DO
NCT03718832
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
AstraZeneca
NCT02284893
Latinos Understanding the Need for Adherence in Diabetes
San Diego State University
NCT03983499
Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
AstraZeneca
NCT00757588
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 25 |
| Phase 3 | 35 |
| Phase 4 | 25 |
Top Sponsors
Named interventions
Most-linked intervention names on Type 2 Diabetes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Type 2 Diabetes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Type 2 Diabetes page
328 registered trials, 120 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 120 Type 2 Diabetes trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Type 2 Diabetes trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Type 2 Diabetes condition card totals 328 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.